Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology
暂无分享,去创建一个
J. Wachowiak | W. Młynarski | T. Szczepański | M. Bartnik | N. Irga-Jaworska | W. Badowska | M. Matysiak | J. Kowalczyk | J. Styczyński | D. Perek | W. Balwierz | B. Dembowska-Baginska | M. Wysocki | E. Adamkiewicz‐Drożynska | T. Ociepa | M. Salamonowicz | A. Szmydki-Baran | K. Semczuk | K. Dzierżanowska-Fangrat | O. Zając‐Spychała | M. Krawczuk-Rybak | K. Czyżewski | P. Zalas‐Więcek | O. Gryniewicz-Kwiatkowska | F. Pierlejewski | L. Chełmecka-Wiktorczyk | R. Tomaszewska | G. Sobol | G. Karolczyk | M. Wieczorek | M. Woszczyk | Z. Gamrot | M. Plonowski | J. Klepacka | W. Stolpa | A. Czajńska-Deptuła | E. Bień | Elwira Kulicka | Z. Małas | A. Urbanek-Dądela | L. Hutnik | P. Zalas-Więcek | O. Gryniewicz‐Kwiatkowska | Aneta Czajńska-Deptuła | Lukasz Hutnik | M. Płonowski | B. Dembowska-Bagińska
[1] J. Wachowiak,et al. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.
[2] James R. Anderson,et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. , 2016 .
[3] M. Cairo,et al. Childhood, adolescent and young adult non‐Hodgkin lymphoma: state of the science , 2016, British journal of haematology.
[4] M. Cairo,et al. Childhood, adolescent and young adult non‐Hodgkin lymphoma: state of the science , 2016, British journal of haematology.
[5] J. Wachowiak,et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[6] K. Kelly. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. , 2015, Blood.
[7] Miriam L. Gonzalez,et al. Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries , 2015, Expert review of hematology.
[8] Q. Hua,et al. Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis , 2015, Journal of chemotherapy.
[9] E. Roilides,et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. , 2014, The Lancet. Oncology.
[10] M. Bassetti,et al. Multidrug-resistant bacteria: what is the threat? , 2013, Hematology. American Society of Hematology. Education Program.
[11] D. Livermore,et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia , 2013, Haematologica.
[12] A. Reiter. Non-Hodgkin Lymphoma in Children and Adolescents , 2013, Klinische Pädiatrie.
[13] M. Hacımustafaoğlu,et al. Catheter-associated Bloodstream Infections in Pediatric Hematology-Oncology Patients , 2013, Pediatric hematology and oncology.
[14] R. Takimoto,et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2012, International Journal of Hematology.
[15] A. Barone. Antibacterial prophylaxis in neutropenic children with cancer , 2011, Pediatric reports.
[16] G. Alangaden,et al. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients , 2010, Expert review of anti-infective therapy.
[17] A. Attarbaschi,et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Dupuis,et al. Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic Leukemia , 2009, The Pediatric infectious disease journal.
[19] H. Einsele,et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.
[20] H. Einsele,et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT , 2008, Bone Marrow Transplantation.
[21] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] G. Escherich,et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia , 2008, Pediatric blood & cancer.
[23] G. Schwarzer,et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. , 2007, The Cochrane database of systematic reviews.
[24] H. Harputluoglu,et al. Rituximab-related viral infections in lymphoma patients , 2007, Leukemia & lymphoma.
[25] K. Schmiegelow,et al. Infections during induction therapy of childhood acute lymphoblastic leukemia – no association to mannose‐binding lectin deficiency , 2006, European journal of haematology.
[26] D. Kontoyiannis,et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.
[27] E. Kimby. Tolerability and safety of rituximab (MabThera). , 2005, Cancer treatment reviews.
[28] Russell E. Lewis,et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.
[29] J. Jernigan,et al. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. , 2005, The Journal of infectious diseases.
[30] C. Kramm,et al. Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma – a rationale for tailored supportive care , 2001, Supportive Care in Cancer.